Introduction
Treatment with oral anticoagulation (OAC) therapy is of pivotal importance to prevent stroke and thromboembolism in atrial fibrillation (AF) patients. 1 More than 82% of AF patients receive OAC therapy in daily practice. 2 Since NOACs have shown an improved net clinical outcome compared to vitamin K antagonists (VKA), these drugs are now recommended as first choice therapy for thrombo-embolic prevention in patients with non-valvular AF. 1, 3 Given the short half-lives of NOACs, correct adherence to the prescribed medication regimen is a critical factor for their safety and effectiveness. [3] [4] [5] Non-adherence or failed persistence can result in poor clinical outcomes and associated increased health care costs. Since systematic monitoring of anticoagulation or medication intake is not performed in NOAC patients (unlike international normalized ratio follow-up in VKA patients), non-adherence may remain undetected and uncorrected.
To date, interventions to improve adherence to NOACs in AF patients are almost absent and/or have shown to be not effective. 8 As a result, there is a need for new initiatives to measure and optimize NOAC therapy adherence.
The aim of this study was to investigate the effect of in-person feedback, based on daily telemonitoring of medication intake, on adherence to NOACs in AF patients. Such a strategy of direct feedback has never been evaluated for NOAC therapy. We assessed its feasibility, effectiveness, and potential health-economic impact.
Methods

Study design and participants
Consecutive AF patients already taking or initiating the once daily (OD) NOAC rivaroxaban or the twice daily (BID) NOAC apixaban were recruited for this single-blind, crossover, randomized controlled trial (RCT). Dabigatran could not be used with the telemonitoring system (as it should be stored in the original package in order to protect it from moisture); edoxaban was not yet approved for use. Patients had to complete three phases of 3 months each ( Figure 1 ). All patients initially received telemonitoring with daily automatic transmissions about their NOAC intake but were randomized to personalized feedback in case of suboptimal adherence or not. Stratification occurred by gender and time since start of NOAC therapy. Patients were crossed over after 3 months. Thereafter, all patients went through a purely observational phase in which medication intake was recorded but not transmitted daily (only read-out after 3 months). The study was conducted in compliance with the Declaration of Helsinki. Ethics approval for the study was obtained from the local ethics committee, and all patients provided written informed consent.
Procedure and measurements
Adherence to NOACs was measured using the electronic Medication Event Monitoring System (MEMS, WestRock, Switzerland). This is a special cap that fits on a medication bottle recording the exact date and time of bottle openings. For the first two telemonitoring phases, patients had to place the medication bottle with the MEMS cap on a wireless reader after each medication intake. Subsequently, the information from the cap was wirelessly and automatically transmitted to an Internet server. A MEMS cap without a display and without showing the medication intake was used in this study. Using the medAmigo software, the medical study team reviewed the adherence data daily on weekdays. This online evaluation allowed to directly give feedback to the patient during the 'feedback phase'. For the last observation phase, patients had to hand in the wireless reader and only used their MEMS medication bottle which still registered daily intake but without the notable telemonitoring transmissions.
During the feedback phase, patients received a phone call in case of an 'unprotected day' (> _3 or > _1 consecutively missed doses for a BID or OD NOAC, respectively, or excess doses during the prior 24 h). 9 Corrective actions were discussed with the patient, conform to the guidelines. 3 Taking adherence (i.e. proportion of prescribed doses taken), regimen adherence (i.e. proportion of days with the correct number of doses taken), and number of unprotected days were calculated based on the MEMS data assuming that every bottle opening represents a medication intake. 10 Pill counts and a refill of the medication bottle were performed after each phase. Morisky scale (MMAS-8), a self-report adherence measure, was completed by the patients at the beginning of each visit. 11 After 9 months, patients completed a questionnaire about their study experience.
Cost-effectiveness analysis
Time investment measurements for MEMS refill visits, daily evaluations of the transferred data, annotating adherence irregularities in the software and direct telephone feedback were converted into total personnel costs (including a 56.6% general overhead cost, as proposed by the national health technology assessment agency). 12 Together with the devices and calling cost, total provider costs were calculated for both observation and feedback phases. These costs were converted into an estimated Figure 1 The study design consisted of three periods of 3 months each, with a crossover between the first two study periods. BID, 'bis in die' or twice a day; NOAC, non-vitamin K antagonist oral anticoagulant; OD, 'omne in die' or once a day; Tm, telemonitoring phase; TmþF, telemonitoring with additional feedback phase. ) . Adherence to NOAC therapy in the large RCTs was considered as an estimated regimen adherence of 88.51%. 8 This value was adopted from the control group of the AEGEAN trial, as no other reliable prospective data or adherence data from the four NOAC RCTs are present. 8 Estimated incremental cost per yearly preventable stroke was calculated based on the adherence percentage revealed by this study.
The yearly expected stroke risk of included patients was estimated by their average CHA 2 DS 2 -VASc score. 15 Stroke is associated with a financial burden of e8943 per hospital episode per patient, based on reimbursement payments made to Belgian hospitals. 16 Base case calculations were modified using different study parameters and cost simulation scenarios as well as variable baseline adherence measurements.
Statistics
Statistical analyses were performed using SPSS 24.0 
Results
Patient population
Fifty-seven AF patients on apixaban or rivaroxaban were invited to participate, of whom 48 (mean age 72 ± 9 years) were included (Table 1; Figure 2 ). No patient stopped OAC treatment during the 9 months study period. Only one patient was switched from apixaban to VKA after 3 months due to thrombosis of the subclavian vein secondary to a pacemaker lead (i.e. persistence of 98%) despite a high taking (97.9%) and regimen (93.8%) adherence.
Effect of telemonitoring-based feedback compared to active telemonitoring
Active telemonitoring already led to a very high taking and regimen adherence (97.4% vs. 93.8%, respectively) (see Supplementary material online, Figure S1 ). There were only 2.6 unprotected days during 3 months. Pill count-based adherence was 97.9%. Adherence further improved through direct feedback: taking adherence increased to 99.0% (P < 0.001), regimen adherence to 96.8% (P = 0.002), and pill count to 99.0% (P = 0.002). The number of unprotected days decreased to 1.5 (P = 0.153). During the active telemonitoring and feedback phases, taking adherence was higher with the OD NOAC (P = 0.002 respectively P = 0.014) although unprotected days were similar (P = 0.272 respectively P = 0.251) (see Supplementary material online, Figure S2 ). Direct feedback significantly improved taking adherence (P = 0.002), regimen adherence (P = 0.002), and pill count (P = 0.001) in the BID NOAC patients where there were no significant effects in the OD NOAC patients (see Supplementary material online, Figure S2 ). No period effects (observed differences between the first two periods irrespective of the intervention) were found in patients on a BID NOAC, while evidence for period effects was present concerning the regimen adherence (P = 0.016) and unprotected days (P = 0.019) in OD NOAC patients.
Effect of the observation phase
Adherence data of seven patients were excluded for the analyses of the observation phase. These patients did not stop NOAC treatment but used the MEMS bottle incorrectly (they used the medication in the MEMS bottle to refill their own pill organizer). Adherence values in the remaining 40 AF patients declined during the observation phase ( Figure 3 ). There was a significant decrease in taking adherence from 99.1% to 94.3% (P = 0.049) and pill count from 99.1% to 96.7% (P = 0.013) compared to the feedback phase. Mean MMAS-8 score was 7.4 ± 0.9 during telemonitoring, 7.8 ± 0.4 during telemonitoring-based feedback, and 7.6 ± 0.5 during the observation phase. The score was an indicator for the adherence during the observation phase, as it was significantly correlated with taking adherence (r s = 0.453; P = 0.003), regimen adherence (r s = 0.498; P = 0.001), unprotected days (r s = -0.474; P = 0.002), and pill count (r s = 0.630; P < 0.001).
Time investments and provided feedback
Daily telemonitoring for 3 months took an average time for the nursing staff of 31 min per patient. To annotate all adherence irregularities in the medAmigo software another 17 min were needed. Direct feedback required 115 phone calls during 3 months, 47.8% triggered by an overdosing and 52.2% by an underdosing. This often revealed patient explanations for the observed irregularity like: (i) data was not sent in due time, while a bottle opening was registered (21.7%), (ii) the patient had no concrete explanation (18.3%), and (iii) the patient took more pills at once out of the MEMS bottle as provision for the following days (12.2%) (see Supplementary material online, Table S1 ). Only in 11.3% of the phone calls, the adherence irregularity was admitted by the patient and corrected when possible. Patients on rivaroxaban were called significantly more often compared to patients taking apixaban (P = 0.006). Another 203 phone calls were performed for other reasons than an unprotected day (see Supplementary material online, Table S2 ), like follow-up on study visits (72.4%), patients asking advice about the dose, intake schedule or temporary pausing of the NOAC (8.4%), and patients asking if telemonitoring data could check whether he/she took his/her NAOC (3.0%).
Cost-effectiveness analysis
To provide observation for 1 year and 100 patients, a total cost of e16 374 would be needed (see Supplementary material online, Table  S3 ). For active telemonitoring with direct feedback, the costs increase to e75 419. Included patients had an anticipated yearly stroke risk of 3.7% (mean CHA 2 DS 2 -VASc score of 3.3). Non-vitamin K antagonist oral anticoagulant therapy at a base case regimen adherence level of 89.6% could reduce this incidence to 1.04%. Assuming a linear gain in efficacy with increasing regimen adherence, feedback-induced improved adherence could reduce the yearly stroke risk further to 0.83%. Therefore, the incremental cost to prevent one stroke in this population would be e344 289/year (e75 419 cost for feedback-
based monitoring minus e1909 for reduced stroke cost, for 0.21 prevented strokes).
Our study showed that telemonitoring-based feedback led to a relative increase in regimen adherence of 69.5% of the maximal possible adherence gain (89.6% to 96.8%). If real-world patients would start with a lower adherence, feedback could lead to a higher absolute gain in regimen adherence. Although total costs would increase (due to more frequent feedback interventions), the cost per percentage increase in regimen adherence would decrease (see Supplementary material online, Table S4 ; Figure 4A) . The cost per Telemonitoring-based feedback improves adherence to NOACs prevented stroke decreases when baseline adherence in the population is lower ( Figure 4B ). Combined with a smarter software system and reduced telemonitoring device cost, the incremental cost to prevent one stroke would be only e15 488/year in patients with a mean CHA 2 DS 2 -VASc of 5 having a baseline adherence of 70%. The costeffectiveness of different scenarios is summarized in Table 2 and Figure 5 .
Patient reported experience
Most patients (87.2%) found the MEMS practical to use and 97.6% of those who received a phone call indicated telephone feedback as useful (see Supplementary material online, Figure S3) . Moreover, 63.8% mentioned that the study increased their awareness about a strict medication adherence, largely attributed to the telemonitoring aspect. Two in three patients indicated that the study motivated them to take their medication more correctly in the future.
Discussion
This is the first report on using automatic telemonitoring and closedloop patient feedback (in analogy with telemonitoring of cardiac implanted devices) as a tool to document and enhance adherence to correct NOAC intake.
Adherence and persistence to NOACs
One of the most accurate ways to measure medication adherence is via electronic monitoring devices, such as the MEMS. 7 Adherence values for NOACs are mostly based on administrative claims and often retrospectively collected. 17, 18 Yao et al. 5 found that only 47.5% of 26 471 AF patients initiating on NOAC had a period of days covered (PDC) > _80% after 1 year. Prescription data from Germany showed that 61.4% of AF patients initiated on rivaroxaban, and 49.5% of dabigatran users had a PDC > _80% after 180 days. 19 It is doubtful if a PDC value > _80% is an acceptable adherence value in NOACs as the effect of missed doses may be more severe due to the short half-life of these drugs. Besides our study, the AEGEAN study is the only prospective trial evaluating the implementation of NOACs in daily care using electronic monitoring. Although reported in 2015, it has not been published so far. AEGEAN showed an adherence to apixaban of 88.51% and a persistence of 90.5% in AF patients receiving standard care after 24 weeks of electronic monitoring. 8 This adherence value is similar compared to the 89.6% taking adherence obtained during the observation phase of our trial. It is still not known how representative these data are for real-world adherence to NOACs. Intriguingly, the four large NOAC RCTs did not report (pill countbased) adherence rates. They only reported discontinuation rates, which varied between 18 and 34% after 2-3 years follow-up. 17, 18 In general, discontinuation rates remain very high, and it is important to resolve this problem. [17] [18] [19] [20] [21] Telemonitoring-based feedback can contribute to this as we showed a high persistence of 98% after 9 months. It is known that an OD dosing regimen is associated with higher adherence. 7, 22, 23 Our study confirmed this in NOAC patients as a higher taking and regimen adherence was found in patients on rivaroxaban during both telemonitoring phases. However, this was not accompanied by a significant difference in unprotected days between both NOAC regimen. In contrast, patients taking rivaroxaban required significantly more telephone calls for an unprotected day. This affirms theoretical considerations that although an OD regimen is the best from an adherence perspective, it may not necessarily be superior to prevent thrombo-embolic complications as a BID NOAC regimen could be more forgiving for missed or extra doses. 9 However, the effect of different NOAC dosing regimens on clinical outcomes and safety still remains to be investigated. More research is also needed concerning the effect of adherence rates and unprotected periods on thrombo-embolic events in NOAC patients. Short-term interruption of NOACs for invasive procedures may not place the patient at a substantially increased risk for cardiovascular or bleeding event, 24 although this does not exclude a potential clinical relevance of repetitive such periods. 
Interventions to increase adherence
The very high adherence values obtained in this study, already in the absence of feedback, are possibly due to the patients' knowing that their adherence was monitored on a daily basis ('radar effect'). Additional phone calls strengthened this feeling, even though in only 11.3% of the phone calls the adherence irregularity was admitted by the patient. A review by Demonceau et al. 25 concluded that an intervention with patient feedback based on electronically monitored adherence data (without direct feedback) could increase medication adherence with 8.8%. Although there was not much room for improvement, our study showed that regimen adherence increased with 4.1% during active telemonitoring and with 7.2% using additional direct feedback. Adherence is a problem worsening over time. 26 One could wonder if telemonitoring should be continued long-term to maintain those very high adherence rates. This requires further study. Another option could be to use this intervention during initiation in order to ensure a correct implementation of the regimen. An alternative is to screen for poorly adherent patients by providing them with a MEMS for a short period without telemonitoring and/or via the Morisky scale. Patients showing poor adherence would qualify for telemonitoring-based feedback. Two other trials already tried to improve the adherence rate for NOACs. The AEGEAN study did not show any impact of an educational program on the adherence for apixaban. 8 The educational program consisted of an educational booklet, reminder tools, and follow-up telephone calls by a virtual clinic. Besides the increased awareness due to the used electronic monitoring device, there were also many planned study visits creating an extra follow-up effect in both the usual care and education group. A possible missed opportunity of AEGEAN was to use the adherence data captured by the electronic devices to provide patient feedback as part of the educational intervention. In a recent study by Labovitz et al., 27 19 NOAC patients were randomized to an intervention group receiving an artificial intelligence application that visually identified the patient, the medication and the confirmed ingestion or to a control group. Visual confirmation of NOAC administration using the app showed a 90.1% adherence after 12 weeks. Pill count-based adherence revealed a value of 90.9% in the control group and 96.4% in the intervention group. Plasma samples taken four times throughout the study showed that 33% of the patients in the control and 100% of those in the intervention group had a drug concentration level above the minimum required therapeutic range. 27 Although not prospectively evaluated, Shore et al. 28 found that pharmacist-based activities (i.e. follow-up and monitoring of adverse events and adherence) led to improved dabigatran adherence. Some studies tried to improve the adherence for VKA; however, results were disappointing. 17, 29 It is still not clear which interventions are the best to optimize adherence to OAC therapy. The European Heart Rhythm Association proposed the development of structured systems to improve AF care, including medication adherence. 3 A possible way is via nurse-coordinated AF clinics. 30 Dedicated nurses can not only discuss adherence issues and advise aids to ensure medication persistence but can also follow-up on renal function, NOAC dosing and adverse events, provide education, etc.
3,31
Cost-effectiveness
If non-adherence to NOACs translates into worse outcomes, it also affects health care costs. 5 We have estimated the cost to prevent one stroke using telemonitoring-based feedback assuming a direct relationship between adherence and stroke. Using simulation, we have highlighted the different elements that have an impact on this figure. We did not include saved costs for reduced bleeding events, since there is no data relating bleeding to the degree of NOAC Figure 5 Different scenarios showing the incremental costs per prevented stroke when study parameters or associated costs would change.
Figures are based on 100 patients receiving telemonitoring with personalized direct feedback for 1 year. BID, 'bis in die' or twice a day; OD, 'omne in die' or once daily.
Telemonitoring-based feedback improves adherence to NOACs adherence. Our data show that telemonitoring will only be costeffective when higher risk, lower adherent patient groups are targeted, and when technology would become cheaper. Apart from the initial hospitalization costs, we did not include costs for stroke rehabilitation or medical follow-up visits, due to the paucity of reliable data. Moreover, a MEMS device is capable to monitor adherence for 3 years, making this intervention more cost-effective when used long-term.
Study limitations
Although this study was limited by its sample size, it was correctly sized to give a good indication about the effects on adherence and time investments of direct telemonitoring-based feedback. There was almost no patient selection bias, as only 15.8% of the patients had to be excluded or was not willing to participate. One can argue that our study design should have included also an observation phase as the first phase, whereas it was only used now as the last phase. The design was decided out of concern that patients would not use the MEMS bottle correctly without the daily monitoring phases first. In retrospect, it would have been more opportune to schedule this phase also as the first, or in random order, since it is conceivable that the adherence values during the observation phase at the end were higher than in real practice. This was most likely due to the 6 months of study experience of the patients which helped them to develop adherence improving habits, outweighing the fact that adherence tends to decrease over time.
Future perspectives
This is the first study proposing a validated approach that can be used to maximize adherence to NOACs, but its impact should be confirmed in a larger RCT. However, one intervention may not fit all patients. New interventions and technologies to enhance adherence need to be developed and tested, ideally in large prospective RCTs taking into account clinical outcomes as a primary endpoint.
Conclusion
Electronic monitoring revealed an unexpectedly high adherence to NOAC therapy in an elderly unselected population. This may be due to highly motivated patients but certainly also to the sense of being watched by technology. Nevertheless, telemonitoring-based rapid and personalized feedback further optimized adherence. Such intervention seems cost-effective when higher risk, poorly adherent patient groups are targeted and when the used technology would become cheaper.
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